Dr. Staskin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11 Nevins St
Ste 303
Boston, MA 02135Phone+1 617-787-8181Fax+1 617-787-4644
Education & Training
Ronald Reagan UCLA Medical CenterUrology, 1984 - 1985
University of Pennsylvania Health SystemResidency, Urology, 1980 - 1984
University of California (San Diego) Medical CenterInternship, Transitional Year, 1979 - 1980
Drexel University College of MedicineClass of 1979
Certifications & Licensure
MA State Medical License 1985 - 2025
NY State Medical License 2002 - 2010- American Board of Urology Urology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Top Doctors: New York Metro Area Castle Connolly, 2005-2009
- Join now to see all
Clinical Trials
- Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US Start of enrollment: 2015 Apr 01
Publications & Presentations
PubMed
- 179 citationsUpdate of AUA Guideline on the Surgical Management of Female Stress Urinary IncontinenceRoger Dmochowski, Jerry Blaivas, E. Ann Gormley, Saad Juma, Mickey M. Karram
The Journal of Urology. 2010-05-01 - 49 citationsEfficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (P...Adrian Wagg, David R. Staskin, Eli Engel, Sender Herschorn, Rita M Kristy
European Urology. 2020-02-01 - 180 citationsPentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study.S. Grant Mulholland, Grannum R. Sant, Phillip M. Hanno, David R. Staskin, Lowell Parsons
Urology. 1990-06-01
Press Mentions
Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingMay 16th, 2022- Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (Vibegron) 75 Mg at 2022 American Urological Association Annual MeetingApril 13th, 2022
- Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (Vibegron) 75 Mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart RateSeptember 13th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
